Market Cap ₹11792 Cr.
Stock P/E 132.0
P/B 5.7
Current Price ₹1299.2
Book Value ₹ 226.2
Face Value 2
52W High ₹1472
Dividend Yield 1.69%
52W Low ₹ 802.2
Founded in 1991, INOXCVA is a global leader in cryogenic equipment and systems. They design, engineer, manufacture, and install solutions for the storage, distribution, and transfer of cryogens across different industries such as industrial gases, LNG, green hydrogen, energy, steel, medical and healthcare, chemicals and fertilizers, aviation and aerospace, pharmaceuticals and construction. The company also offers equipment and turnkey solutions for scientific and industrial research involving cryogenic applications. INOXCVA relies on its pillars of consistent quality, persistent innovation, and professional excellence to realize its ideas and accomplish its goals. They has a product range with applications from 'deep in the earth' to 'high up in space'. It is one of the largest exporters of cryogenic tanks from India.Their vision is to become the world's best integrated cryogenic solutions enterprise along with a leadership position across products and markets.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2022 | Dec 2023 |
|---|---|---|
| Net Sales | 244 | 290 |
| Other Income | 6 | 5 |
| Total Income | 250 | 295 |
| Total Expenditure | 192 | 224 |
| Operating Profit | 58 | 71 |
| Interest | 1 | 2 |
| Depreciation | 4 | 5 |
| Exceptional Income / Expenses | 0 | 0 |
| Profit Before Tax | 54 | 64 |
| Provision for Tax | 13 | 15 |
| Profit After Tax | 41 | 49 |
| Adjustments | 0 | 0 |
| Profit After Adjustments | 41 | 49 |
| Adjusted Earnings Per Share | 4.5 | 5.4 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 460 | 433 | 562 | 731 | 649 | 595 | 783 | 966 | 534 |
| Other Income | 5 | 16 | 13 | 10 | 43 | 22 | 21 | 18 | 11 |
| Total Income | 465 | 449 | 574 | 741 | 692 | 617 | 804 | 984 | 545 |
| Total Expenditure | 478 | 422 | 525 | 563 | 516 | 466 | 615 | 762 | 416 |
| Operating Profit | -13 | 27 | 49 | 177 | 176 | 151 | 189 | 223 | 129 |
| Interest | 35 | 41 | 28 | 27 | 25 | 7 | 2 | 4 | 3 |
| Depreciation | 32 | 23 | 9 | 9 | 12 | 12 | 12 | 14 | 9 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -79 | -38 | 11 | 141 | 138 | 133 | 174 | 205 | 118 |
| Provision for Tax | 7 | -0 | 10 | -53 | 46 | 35 | 44 | 52 | 28 |
| Profit After Tax | -86 | -38 | 1 | 193 | 92 | 97 | 130 | 153 | 90 |
| Adjustments | 22 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Profit After Adjustments | -65 | -38 | 1 | 193 | 92 | 98 | 130 | 153 | 90 |
| Adjusted Earnings Per Share | -7.1 | -4.1 | 0.1 | 21.3 | 10.1 | 10.8 | 14.4 | 16.8 | 9.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 23% | 14% | 11% | 0% |
| Operating Profit CAGR | 18% | 8% | 35% | 0% |
| PAT CAGR | 18% | 18% | 173% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 29% | 30% | 59% | 12% |
| ROCE Average | 38% | 36% | 37% | 24% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 70 | 19 | 19 | 210 | 279 | 372 | 502 | 549 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 202 | 213 | 88 | 59 | 6 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1 | 4 | 14 | -43 | 15 | 21 | 22 | 22 |
| Total Current Liabilities | 530 | 587 | 646 | 448 | 326 | 294 | 373 | 577 |
| Total Liabilities | 804 | 824 | 768 | 674 | 627 | 687 | 897 | 1148 |
| Fixed Assets | 296 | 276 | 96 | 94 | 110 | 102 | 134 | 164 |
| Other Non-Current Assets | 103 | 8 | 80 | 84 | 3 | 56 | 10 | 10 |
| Total Current Assets | 406 | 539 | 592 | 496 | 514 | 521 | 743 | 963 |
| Total Assets | 804 | 824 | 768 | 674 | 627 | 687 | 897 | 1148 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 17 | 10 | 3 | 2 | 37 | 30 | 2 | 1 |
| Cash Flow from Operating Activities | 93 | 54 | 83 | 85 | 188 | 231 | 97 | 178 |
| Cash Flow from Investing Activities | -23 | 5 | 88 | 143 | -5 | -159 | -75 | -11 |
| Cash Flow from Financing Activities | -64 | -55 | -169 | -186 | -168 | -99 | -26 | -154 |
| Net Cash Inflow / Outflow | 6 | 4 | 2 | 43 | 15 | -27 | -4 | 13 |
| Closing Cash & Cash Equivalent | 10 | 3 | 2 | 37 | 30 | 2 | 1 | 14 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -7.11 | -4.14 | 0.15 | 21.3 | 10.13 | 10.81 | 14.38 | 16.83 |
| CEPS(Rs) | -6.03 | -1.56 | 1.18 | 22.34 | 11.45 | 12.04 | 15.71 | 18.36 |
| DPS(Rs) | 0.2 | 0 | 0 | 0.2 | 0.4 | 0 | 1.5 | 22 |
| Book NAV/Share(Rs) | 7.73 | 2.11 | 2.14 | 23.09 | 30.79 | 40.99 | 55.34 | 60.54 |
| Core EBITDA Margin(%) | -3.78 | 2.43 | 6.47 | 22.88 | 20.46 | 21.67 | 21.42 | 21.16 |
| EBIT Margin(%) | -9.52 | 0.76 | 7.04 | 23.01 | 25.24 | 23.47 | 22.55 | 21.61 |
| Pre Tax Margin(%) | -16.86 | -8.46 | 2.01 | 19.26 | 21.31 | 22.31 | 22.26 | 21.23 |
| PAT Margin (%) | -18.36 | -8.45 | 0.24 | 26.47 | 14.17 | 16.39 | 16.67 | 15.81 |
| Cash Profit Margin (%) | -11.63 | -3.2 | 1.91 | 27.75 | 16.01 | 18.37 | 18.22 | 17.25 |
| ROA(%) | -10.75 | -4.61 | 0.17 | 26.82 | 14.14 | 14.84 | 16.48 | 14.93 |
| ROE(%) | -123.27 | -84.03 | 6.95 | 168.86 | 37.61 | 29.93 | 29.85 | 29.04 |
| ROCE(%) | -7.51 | 0.58 | 9.33 | 43.38 | 35.68 | 32.58 | 36.1 | 38.12 |
| Receivable days | 37.51 | 54.48 | 67.7 | 68.07 | 83 | 79.68 | 44.5 | 41.76 |
| Inventory Days | 227.56 | 240.1 | 152.07 | 99.73 | 107.66 | 94.21 | 109.2 | 138.93 |
| Payable days | 86.38 | 103.54 | 83.6 | 38.92 | 25.6 | 24.51 | 31.06 | 44.2 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.12 | 1.27 | 0.44 | 0.31 | 0.15 | -0.22 | 0.07 | -0.05 |
| EV/Core EBITDA(x) | -39.11 | 20.59 | 5.08 | 1.28 | 0.54 | -0.87 | 0.28 | -0.2 |
| Net Sales Growth(%) | 0 | -5.92 | 29.78 | 30.06 | -11.15 | -8.37 | 31.61 | 23.4 |
| EBIT Growth(%) | 0 | 107.5 | 1075.92 | 325.31 | -2.55 | -14.81 | 26.48 | 18.24 |
| PAT Growth(%) | 0 | 56.59 | 103.58 | 0 | -52.44 | 6 | 33.87 | 17.02 |
| EPS Growth(%) | 0 | 41.88 | 103.58 | 0 | -52.44 | 6.65 | 33.06 | 17.02 |
| Debt/Equity(x) | 7.48 | 28.49 | 13.48 | 1.36 | 0.52 | 0.16 | 0.09 | 0 |
| Current Ratio(x) | 0.77 | 0.92 | 0.92 | 1.11 | 1.58 | 1.77 | 1.99 | 1.67 |
| Quick Ratio(x) | 0.21 | 0.42 | 0.64 | 0.61 | 1.08 | 1.27 | 1.13 | 0.95 |
| Interest Cover(x) | -1.3 | 0.08 | 1.4 | 6.13 | 6.43 | 20.35 | 75.96 | 56.64 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 |
|---|---|---|
| Promoter | 75 | 75 |
| FII | 4.65 | 6.14 |
| DII | 6.48 | 6.59 |
| Public | 13.87 | 12.27 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Dec 2023 | Mar 2024 |
|---|---|---|
| Promoter | 6.81 | 6.81 |
| FII | 0.42 | 0.56 |
| DII | 0.59 | 0.6 |
| Public | 1.26 | 1.11 |
| Others | 0 | 0 |
| Total | 9.08 | 9.08 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
